Pubblicazioni scientifiche

Avnet S.; Lemma S.; Errani C.; Falzetti L.; Panza E.; Columbaro M.; Nanni C.; Baldini N., Benign albeit glycolytic: MCT4 expression and lactate release in giant cell tumour of bone, «BONE», 2020, 134, pp. 115302 - N/A [Articolo in rivista]

Guaraldi G.; Milic J.; Cozzi-Lepri A.; Pea F.; Mussini C., Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply, «THE LANCET. RHEUMATOLOGY», 2020, 2, pp. E739 - E740 [Replica/breve intervento (e simili)]

Minardi R.; Licchetta L.; Baroni M.C.; Pippucci T.; Stipa C.; Mostacci B.; Severi G.; Toni F.; Bergonzini L.; Carelli V.; Seri M.; Tinuper P.; Bisulli F., Whole-exome sequencing in adult patients with developmental and epileptic encephalopathy: It is never too late, «CLINICAL GENETICS», 2020, 98, pp. 477 - 485 [Articolo in rivista]

Dimartino P.; Mariani V.; Marconi C.; Minardi R.; Bramerio M.; Licchetta L.; Menghi V.; Morandi L.; Magini P.; Mongelli P.; Cardinale F.; Seri M.; Tinuper P.; Tassi L.; Pippucci T.; Bisulli F., Accurate Detection of Hot-Spot MTOR Somatic Mutations in Archival Surgical Specimens of Focal Cortical Dysplasia by Molecular Inversion Probes, «MOLECULAR DIAGNOSIS & THERAPY», 2020, 24, pp. 571 - 577 [Articolo in rivista]

Dall'Olio F.G.; Abbati F.; Facchinetti F.; Massucci M.; Melotti B.; Squadrilli A.; Buti S.; Formica F.; Tiseo M.; Ardizzoni A., CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 4 [Articolo in rivista] Open Access

Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F., The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?, «CANCERS», 2020, 12, pp. 1 - 21 [Articolo in rivista] Open Access

Cojutti P.G.; Lazzarotto D.; Candoni A.; Dubbini M.V.; Zannier M.E.; Fanin R.; Pea F., Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2020, 75, pp. 3029 - 3037 [Articolo in rivista] Open Access

Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, pp. 1 - 18 [Articolo in rivista]

Pea F., Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations, «JOURNAL OF INFECTION AND CHEMOTHERAPY», 2020, 26, pp. 900 - 907 [Articolo in rivista]

Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A., Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2020, 8, pp. 1 - 3 [Articolo in rivista] Open Access

Soriano A.; Rossolini G.M.; Pea F., The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs), «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2020, 18, pp. 415 - 422 [Articolo in rivista] Open Access

Sartore-Bianchi A.; Lonardi S.; Martino C.; Fenocchio E.; Tosi F.; Ghezzi S.; Leone F.; Bergamo F.; Zagonel V.; Ciardiello F.; Ardizzoni A.; Amatu A.; Bencardino K.; Valtorta E.; Grassi E.; Torri V.; Bonoldi E.; Sapino A.; Vanzulli A.; Regge D.; Cappello G.; Bardelli A.; Trusolino L.; Marsoni S.; Siena S., Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, «ESMO OPEN», 2020, 5, pp. 1 - 8 [Articolo in rivista] Open Access

Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A., Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience, «LUNG CANCER», 2020, 149, pp. 5 - 9 [Articolo in rivista]

Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A., New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [Articolo in rivista] Open Access

Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [Articolo in rivista] Open Access

Brandes A.A.; Ardizzoni A.; Artioli F.; Cappuzzo F.; Cavanna L.; Frassineti G.L.; Frassoldati A.; Leonardi F.; Longo G.; Maestri A.; Tassinari D.; Franceschi E.; Nunno V.D.; Pinto C., Fighting cancer in coronavirus disease era: Organization of work in medical oncology departments in Emilia Romagna region of Italy, «FUTURE ONCOLOGY», 2020, 16, pp. 1433 - 1439 [Articolo in rivista] Open Access

Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [Articolo in rivista]

Dall'Olio F.G.; Maggio I.; Massucci M.; Mollica V.; Fragomeno B.; Ardizzoni A., ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data, «LUNG CANCER», 2020, 145, pp. 95 - 104 [Articolo in rivista]

Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A., Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL), «BRITISH JOURNAL OF CANCER», 2020, 123, pp. 26 - 32 [Articolo in rivista] Open Access

Ponce Aix S.; Talbot D.; Govindan R.; Dols M.C.; Postmus P.E.; Lewanski C.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Ong T.J.; Morgensztern D., Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 749 - 762 [Articolo in rivista]